Of those who receive new agents.

Of those who receive new agents, life expectancy increased by 6.8 months and lifetime costs increased $ 37,100, corresponding to a price of $ 66,200 per life year gained. After further adjustments, the cost per quality-adjusted life year gained was $ 99 says lead study author Howard, Associate Professor of Health Policy and Management.

David H. And his colleagues at the Emory University Rollins School of Public Health used a cancer registry database, in order to measure trends in life expectancy and lifetime medical costs in 4,665 patients aged 66 and older diagnosed metastatic colon cancer between 1995 and 2005. Patients were treated according to whether they received classified one or more of the six chemotherapeutic agents approved for the treatment of metastatic colorectal cancer zwischen 1996 and 2004.The other universities involved in in the UNC-led Collaboratory are Case Western Reserve University, Johns Hopkins University in, the University of California, Davis, University of California at, of Los Angeles, University of California at, San Diego, the Gladstone Institutes, the University of California, San Francisco, University of Minnesota and the University of Utah.